文献速递乳腺癌

LEO研究:亮丙瑞林联合来曲唑±依维莫司治疗绝经前HR+/HER2-转移性乳腺癌

Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
PubMed 文献 · Eur J Cancer · 2020-12-31

随机II期LEO试验纳入137例绝经前HR+/HER2-复发/转移性乳腺癌患者,随机2:1接受亮丙瑞林+来曲唑+依维莫司或亮丙瑞林+来曲唑,主要终点PFS。中位随访32.4个月,总体PFS无显著差异,但内脏转移亚组PFS显著延长,CBR显著提高。

要点

  • 联合依维莫司未显著改善总体人群PFS(HR 0.73,P=0.137)
  • 内脏转移亚组中联合组PFS显著延长(16.4 vs 9.5个月,P=0.048)
  • 联合组临床获益率显著更高(83% vs 62%,P=0.010)

核心结论

  • 在绝经前HR+/HER2-转移性乳腺癌中,卵巢抑制下来曲唑联合依维莫司较单用来曲唑未显著延长总体PFS。
  • 内脏转移患者中联合依维莫司PFS显著延长,临床获益率显著提高。

研究设计与样本

  • 随机II期LEO试验,纳入137例绝经前HR+/HER2-复发/转移性乳腺癌患者,按2:1随机分配至依维莫司组或来曲唑组。
  • 患者既往接受过他莫昔芬±GnRH激动剂治疗(辅助或转移阶段),中位年龄44岁(范围24-56)。

主要发现

  • 中位随访32.4个月,依维莫司组中位PFS 18.1个月,来曲唑组13.8个月(HR 0.73,P=0.137)。
  • 内脏转移亚组中,依维莫司组中位PFS 16.4个月,来曲唑组9.5个月(P=0.048)。
  • 临床获益率依维莫司组83%,来曲唑组62%(P=0.010);两组OS均未达到,ORR相似。
  • 依维莫司组最常见3/4级不良事件为中性粒细胞减少、丙氨酸氨基转移酶升高和贫血。

关键数值与推荐

  • 总体人群PFS:HR 0.73,P=0.137。
  • 内脏转移亚组PFS:16.4个月 vs 9.5个月,P=0.048。
  • 临床获益率:83% vs 62%,P=0.010。
  • 75%患者为内分泌敏感性疾病,61%有内脏转移。

临床怎么用

  • 对于他莫昔芬暴露过的绝经前HR+/HER2-转移性乳腺癌伴内脏转移患者,可考虑卵巢抑制下来曲唑联合依维莫司。
  • 联合方案需关注中性粒细胞减少、肝酶升高和贫血等3/4级不良事件。

局限性

  • II期随机试验样本量有限(137例),总体PFS差异未达统计学显著。
  • 内脏转移亚组分析为探索性,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the randomised phase II LEO trial, we investigated the effect of adding everolimus (EVE) to letrozole (LET) in ovarian-suppressed premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent/metastatic breast cancer. METHODS: Patients with progression or prior exposure to tamoxifen with or without gonadotropin-releasing hormone agonists, either sequentially or concurrently, in adjuvant or metastatic setting were randomly assigned (2:1) to the EVE arm (leuprorelin + LET + EVE) or the LET arm (leuprorelin + LET) until disease progression or unacceptable toxicity. The primary end-point was progression-free survival (PFS). Secondary end-points included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. RESULTS: Between January 2014 and October 2018, 137 patients were enrolled (median age, 44 years [range, 24-56]). Of them, 75% had endocrine-sensitive disease, and 61% had visceral metastasis. With the median follow-up of 32.4 months, the median PFS was 18.1 months in the EVE arm and 13.8 months in the LET arm (HR 0.73, P = 0.137). Among patients with visceral metastases, the median PFS was significantly longer in the EVE arm (16.4 versus 9.5 months, P = 0.048). The median OS was not reached in both arms. The CBR was significantly higher in the EVE arm (83% versus 62%, P = 0.010). The ORR was similar between the two arms. The most common grade 3/4 adverse events in the EVE arm were neutropenia, alanine aminotransferase elevation and anaemia. CONCLUSIONS: EVE plus LET with ovarian-suppression resulted in longer PFS in tamoxifen-exposed HR+, HER2- metastatic breast cancer patients with visceral metastasis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jeong JH, Kim JE, Ahn JH, et al. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. Eur J Cancer. 2020. PMID: 33388491. doi:10.1016/j.ejca.2020.11.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。